A late Christmas present for Allogene

Three months is all it has taken for the FDA to lift its hold on Allogene’s clinical pipeline. The news, revealed today just as the JP Morgan conference is getting under way, will be welcomed by investors who had seen 45% of the company’s market cap erased since October 8.